Surge In Partnerships And Licensing In China Highlights Need For Greater Flexibility
This article was originally published in PharmAsia News
Executive Summary
As cross-border deals rise rapidly and finding new partners becomes harder in China, multinational drug makers must be flexible in their deal strategies. Seasoned executives from AstraZeneca, Bayer, Merck and Chinese startup Ascletis offer insights on what to look for in a dynamic market.